A Case of TAFRO Syndrome Developed after COVID-19 Vaccination.
Autorzy:
Hirose H; Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan. Suzuki H; Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.; Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan. UmezawaY; Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan. Iwasaki M; Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan. Fukuda H; Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan. Takahara H; Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan. Tomita S; Department of Pathology, Juntendo University Urayasu Hospital, Chiba, Japan. Suzuki Y; Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło:
Case reports in nephrology [Case Rep Nephrol] 2023 Dec 04; Vol. 2023, pp. 7292895. Date of Electronic Publication: 2023 Dec 04 (Print Publication: 2023).
Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
Autorzy:
Kanao K; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan. Takahashi T; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan. UmezawaY; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan. Okabe T; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan. Kaneko G; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan. Shirotake S; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan. Nishimoto K; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan. Oyama M; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama-Pref, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Oct 20; Vol. 17 (10), pp. e0276081. Date of Electronic Publication: 2022 Oct 20 (Print Publication: 2022).
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
Autorzy:
Okubo Y; Department of Dermatology, Tokyo Medical University, Tokyo, Japan. UmezawaY; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan. Sakurai S; UCB Pharma, 8 Chome-17-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. . Hoshii N; UCB Pharma, 8 Chome-17-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. Nakagawa H; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło:
Dermatology and therapy [Dermatol Ther (Heidelb)] 2022 Jun; Vol. 12 (6), pp. 1397-1415. Date of Electronic Publication: 2022 May 27.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
